Search research articles
Contact Us
Filters
Showing results (71-80 of 116) with videos related to
Page
of 12
Sort By:
International Journal of Hematology
|
May 24, 2019
Impact of chromosomal abnormalities on the efficacy of lenalidomide plus dexamethasone treatment in patients with relapsed/refractory multiple myeloma
Takashi Yoshida, Masaki Ri, Haruna Fujinami, et al.
Hematological Oncology
|
November 25, 2022
Aberrant tryptophan metabolism leads to unfavorable outcomes in lenalidomide-treated myeloma patients
Arisa Asano, Masaki Ri, Ayako Masaki, et al.
Cancer Science
|
February 16, 2020
Expression, mutation, and methylation of cereblon-pathway genes at pre- and post-lenalidomide treatment in multiple myeloma
Takuto Tachita, Shiori Kinoshita, Masaki Ri, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 23, 2024
Clinical Significance of Cytomegalovirus Reactivation in Patients With Plasma Cell Dyscrasia Who Were Treated With Anti-CD38 Monoclonal Antibody: A Retrospective Analysis in a Single Institution
Naohiro Matsunaga, Tomotaka Suzuki, Nozomi Nishitarumizu, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
June 5, 2013
Autologous Tax-specific CTL therapy in a primary adult T cell leukemia/lymphoma cell-bearing NOD/Shi-scid, IL-2Rγnull mouse model
Ayako Masaki, Takashi Ishida, Susumu Suzuki, et al.
Hematological Oncology
|
September 17, 2020
Clinical significance of tryptophan catabolism in follicular lymphoma
Ayako Masaki, Takashi Ishida, Yasuhiro Maeda, et al.
Annals of Hematology
|
November 12, 2015
Labial salivary gland biopsy for diagnosing immunoglobulin light chain amyloidosis: a retrospective analysis
Tomotaka Suzuki, Shigeru Kusumoto, Taro Yamashita, et al.
Molecular Cancer Therapeutics
|
September 27, 2012
RSK2(Ser227) at N-terminal kinase domain is a potential therapeutic target for multiple myeloma
Yuji Shimura, Junya Kuroda, Masaki Ri, et al.
International Journal of Hematology
|
December 31, 2015
Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma
Haruhito Totani, Masaki Ri, Chie Kato, et al.
Oncotarget
|
March 9, 2018
Potent anti-tumor activity of a syringolin analog in multiple myeloma: a dual inhibitor of proteasome activity targeting β2 and β5 subunits
Takashi Yoshida, Masaki Ri, Takashi Kanamori, et al.
Page
of 12
Search research articles
Search
Showing results (71-80 of 116) with videos related to
Sort By:
Page
of 12
International Journal of Hematology
|
May 24, 2019
Impact of chromosomal abnormalities on the efficacy of lenalidomide plus dexamethasone treatment in patients with relapsed/refractory multiple myeloma
Takashi Yoshida, Masaki Ri, Haruna Fujinami, et al.
Hematological Oncology
|
November 25, 2022
Aberrant tryptophan metabolism leads to unfavorable outcomes in lenalidomide-treated myeloma patients
Arisa Asano, Masaki Ri, Ayako Masaki, et al.
Cancer Science
|
February 16, 2020
Expression, mutation, and methylation of cereblon-pathway genes at pre- and post-lenalidomide treatment in multiple myeloma
Takuto Tachita, Shiori Kinoshita, Masaki Ri, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 23, 2024
Clinical Significance of Cytomegalovirus Reactivation in Patients With Plasma Cell Dyscrasia Who Were Treated With Anti-CD38 Monoclonal Antibody: A Retrospective Analysis in a Single Institution
Naohiro Matsunaga, Tomotaka Suzuki, Nozomi Nishitarumizu, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
June 5, 2013
Autologous Tax-specific CTL therapy in a primary adult T cell leukemia/lymphoma cell-bearing NOD/Shi-scid, IL-2Rγnull mouse model
Ayako Masaki, Takashi Ishida, Susumu Suzuki, et al.
Hematological Oncology
|
September 17, 2020
Clinical significance of tryptophan catabolism in follicular lymphoma
Ayako Masaki, Takashi Ishida, Yasuhiro Maeda, et al.
Annals of Hematology
|
November 12, 2015
Labial salivary gland biopsy for diagnosing immunoglobulin light chain amyloidosis: a retrospective analysis
Tomotaka Suzuki, Shigeru Kusumoto, Taro Yamashita, et al.
Molecular Cancer Therapeutics
|
September 27, 2012
RSK2(Ser227) at N-terminal kinase domain is a potential therapeutic target for multiple myeloma
Yuji Shimura, Junya Kuroda, Masaki Ri, et al.
International Journal of Hematology
|
December 31, 2015
Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma
Haruhito Totani, Masaki Ri, Chie Kato, et al.
Oncotarget
|
March 9, 2018
Potent anti-tumor activity of a syringolin analog in multiple myeloma: a dual inhibitor of proteasome activity targeting β2 and β5 subunits
Takashi Yoshida, Masaki Ri, Takashi Kanamori, et al.
Page
of 12